Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by alleyesonmeon May 16, 2024 6:34pm
186 Views
Post# 36044451

U.S.A, novel drugs, and NEW DRUG applications.

U.S.A, novel drugs, and NEW DRUG applications.Have been submitted by pharmaceutical clients who've referenced the DMF held by MPL...this was mentioned in the MD&A and in the CC. Similar info is published on the investors deck found on the corporate website..I would image once rescheduling takes effect FDA approval is more easily attainable as opposed to the current schedule the API falls under... considering this information has been on the investor deck for well over a year the application has been sitting with the FDA for a LONG time....if approved this stock will explode and my view on the holdup has to do with the schedule and once this stance officially changes we could see approval shortly after..for this tight lipped management team to bring up the new drug applications for the first time on CC and MD&A is significant IMO
<< Previous
Bullboard Posts
Next >>